Valerio Therapeutics, Abivax team up on preclinical RNA therapeutics for immune-mediated inflammatory diseases

• Valerio Therapeutics outlined a plan to advance its RNA-based precision therapy pipeline toward clinical testing within 18–24 months.
• No clinical trial has been launched yet. No study results have been presented. No future results presentation was disclosed.
• Pipeline focus remains immune-mediated inflammatory diseases, aiming for targeted elimination of pathogenic immune cells, plus an oncology program designed to reinvigorate exhausted T cells.
• Strategy targets selection of up to two drug candidates within 12–18 months, positioning the portfolio for a first-in-human study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valerio Therapeutics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260716004647) on July 16, 2026, and is solely responsible for the information contained therein.